Fig. 6: In vivo cardiac function evaluation. | Nature Communications

Fig. 6: In vivo cardiac function evaluation.

From: Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron

Fig. 6

a Dosing schedule of the in vivo cardiac function evaluation. b, c Body weights (b) and survival rates (c) of mice from different groups during the evaluation period. n = 10. Data are presented as mean ± s.d. d H&E staining and Masson’s Trichrome staining images of the heart sections in different groups. e Impaired zone percentages on the heart tissue of mice in different groups revealed by the Masson’s Trichrome staining imaging. f–h Plasma CK (f), AST (g) and LDH (h) levels of each mouse in different groups at the end of the evaluation period. n = 4. Data are presented as mean ± s.d. Statistical significance (to the control group) is assessed by Student t’s two-tailed test. *P < 0.05, **P < 0.01 and n.s. for non-significant.

Back to article page